Eris Lifesciences posted a 19 percent net profit rise to ₹99.7 crore in Q3, with revenue up 10 percent to ₹807 crore and plans to acquire the remaining 30 percent in Swiss Parenterals for ₹423 crore.
1 Min Read
Eris Lifesciences reported a steady operating performance in the December quarter, supported by healthy growth in revenue and profitability.
Eris Lifesciences Limited’s net profit rose 19% year-on-year to ₹99.7 crore in Q3, compared with ₹83.7 crore in the corresponding quarter last year. Revenue from operations increased 10% YoY to ₹807 crore, up from ₹732 crore in the same period last year.
EBITDA grew 11% YoY to ₹282.3 crore from ₹254.7 crore a year ago. EBITDA margin improved marginally to 35% in Q3, compared with 34.8% in the year-ago quarter, reflecting stable cost management and operating leverage.
Read More: Eris Lifesciences to acquire remaining 30% in Swiss Parenterals for ₹423 crore
